Healthcare Sales & Marketing Network News: SEER

Searching News Database: SEER

HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Jun 2024
TALVEY(R) (talquetamab-tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Sep 2023
nRichDX Launches New CTC Enrichment Kit
Diagnostics Oncology Product Launch

HSMN NewsFeed - 1 Apr 2021
FDA Grants Breakthrough Therapy Designation for Taiho Oncology's Futibatinib for Treatment of Advanced Cholangiocarcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Jun 2020
Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Mar 2019
FDA Grants De Novo for the HemoSonics Quantra(R) QPlus System; This Revolutionary Diagnostic Provides Unique Information for Accessing Coagulation at the Point of Care; Now Commercially Available in US
Devices Diagnostics FDA

HSMN NewsFeed - 27 Aug 2018
Vyxeos(R) Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 1 Jun 2018
PENTAX Medical Introduces Next-Generation C2 CryoBalloon(TM) Ablation System for Treatment of Barrett's Esophagus
Devices Gastroenterology Product Launch

HSMN NewsFeed - 16 May 2018
Photocure Announces Blue Light Cystoscopy with Cysview(R) Now Available for Surveillance of Bladder Cancer
Devices Diagnostics Oncology Product Launch

HSMN NewsFeed - 16 Feb 2018
Photocure Announces U.S. FDA Approval of New Indication for Blue Light Cystoscopy with Cysview(R)
Devices Oncology FDA

HSMN NewsFeed - 20 Jun 2017
NCCN Guidelines Compliance for Chest CT Reduces False Positives and Decreases Health Care Spending in Breast Cancer, Study Finds
Devices Oncology Radiology

HSMN NewsFeed - 17 Feb 2017
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2016
Genomic Health Announces Results from Multiple Oncotype DX(R) Studies, Reinforcing its Impact in Delivering Precision Medicine to Breast Cancer Patients Around the World
Diagnostics Personalized Medicine Oncology

HSMN NewsFeed - 5 Sep 2016
Eisai Bewildered as German Institute for Quality and Efficiency in Health Care (IQWIG) Fails to Recognise Additional Benefit of Halaven(R) (eribulin) in the Treatment of Advanced Liposarcoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 31 Aug 2016
XALKORI(R) (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 25 Nov 2015
Pfizer Receives European Approval to Expand Use of XALKORI(R) (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Nov 2015
Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI(R) (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Oct 2015
Merrimack Announces U.S. FDA Approval of ONIVYDE(TM) (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Aug 2015
GE Healthcare First to Receive FDA Clearance for Low Dose CT Lung Cancer Screening
Devices Oncology Radiology FDA

HSMN NewsFeed - 12 May 2015
Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation for Evofosfamide for the Treatment of Patients Living With Advanced Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Feb 2015
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 28 Apr 2014
Vermillion Launches ASPiRA LABS
Diagnostics Personalized Medicine Oncology

HSMN NewsFeed - 6 Jun 2013
Veran Medical Technologies Launches SPiNDrive(R) 2.0, as American College of Chest Physicians Recognizes This Technology in New Guidelines
Devices Oncology Product Launch

HSMN NewsFeed - 11 Mar 2013
Precision Therapeutics Announces Topline Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian Cancer using Personalized Chemotherapy Diagnostic ChemoFx(R)
Diagnostics Oncology Personalized Medicine

HSMN NewsFeed - 18 Sep 2012
DFINE Announces Full U.S. Commercial Release of STAR Tumor Ablation System
Devices Orthopaedic Neurosurgery Oncology

HSMN NewsFeed - 26 Apr 2012
Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 17 Apr 2012
Statement by Dr. Eugen Hug, Chief Medical Officer of ProCure Treatment Centers, Regarding the University of North Carolina Study Comparing Proton Therapy and Intensity Modulated Radiation Therapy (IMRT) for Prostate Cancer
Devices Oncology

HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 31 May 2011
Fujirebio Diagnostics, Inc. Receives FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer
Diagnostics Oncology FDA

HSMN NewsFeed - 18 Jan 2011
GE Healthcare Named Exclusive Distributor of Veran ig4 Navigation Systems in United States
Devices Oncology Radiology Distribution

HSMN NewsFeed - 11 Jun 2010
Salient Surgical Technologies Sues Bovie Medical for Patent Infringement
Devices Surgery Litigation

HSMN NewsFeed - 9 Apr 2010
CTI Receives Complete Response Letter from the FDA for Pixantrone NDA; CTI to File for Expanded Access for Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Mar 2009
Spectrum Pharmaceuticals Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 23 Feb 2009
Spectrum Pharmaceuticals Poised to Acquire 100% Interest in RIT Oncology LLC Joint Venture upon CTI's Fulfillment of Closing Conditions
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 19 Feb 2009
Bovie Medical Corporation Reports Success with Seer Tissue Resection Device Sales and Marketing
Devices Surgery

HSMN NewsFeed - 22 Jan 2009
Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Dec 2008
Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2008
Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Dec 2008
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Nov 2008
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Oct 2008
Bovie Medical Corporation Announces CE Mark and Submission of 510(K) Application for SEER Tissue Resection Device; Commences SEER Shipments in European Union
Devices Regulatory FDA

HSMN NewsFeed - 20 Oct 2008
High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Aug 2008
Craig W. Philips Takes Helm at CTI
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Jun 2008
CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2008
ABRAXANE(R) in Combination with Trastuzumab and Carboplatin Evaluated as First-Line Treatment for Patients with HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2008
Combination Therapy of Solvent-Free ABRAXANE(R) and the Targeted Therapy Bevacizumab Evaluated as First-Line Treatment for Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Dec 2007
Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 4 Dec 2007
AVAX Technologies Appoints Dr. Francois Martelet as President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Nov 2007
Nexavar First FDA-Approved Drug Therapy for Liver Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Nov 2007
AVAX Technologies announces the initiation of its Phase III Registration trial of M-Vax(R) in Metastatic Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Oct 2007
Nexavar Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 12 Sep 2007
Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Aug 2007
Cell Therapeutics, Inc. (CTI) Enters Agreement to Acquire Lymphoma Drug Zevalin(R) from Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions Oncology

HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2007
OVArian TUmor REsponse ('OVATURE') Trial Enrolls First U.S. Patient
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2007
Indevus Announces Authorization for Approval of VANTAS(R) in Selected European Countries
Biopharmaceuticals Regulatory

HSMN NewsFeed - 22 May 2007
Outcomes Data Continue to Demonstrate Value of Cytogen's PROSTASCINT(R) to Predict Prognosis in Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Apr 2007
Wyeth Responds to Special Report Published in New England Journal of Medicine

HSMN NewsFeed - 13 Mar 2007
Cell Therapeutics, Inc. (CTI) Files for Special Protocol Assessment (SPA) for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 May 2006
Matritech's NMP22(R) BladderChek(R) Test Could Save Lives and Reduce Expense in Screening High Risk Populations for Bladder Cancer
Diagnostics Oncology

HSMN NewsFeed - 15 May 2006
U.S. FDA Grants Orphan Drug Designation to OXiGENE's Lead Clinical Candidate, Combretastatin A4P (CA4P), for the Treatment of Ovarian Cancer
Biopharmaceuticals Oncology FDA

Return to NewsFeed

Additional items found! 6

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 6 additional stories matching:
SEER
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!